Lunit Joins 'CancerX' First Official Project... Preparing to Supply AI Solutions in the US

First Project to Conquer Cancer 'Solution Catalog'
US Medical Institutions Can Immediately Utilize Lunit Products and Solutions

Medical AI company Lunit announced on the 10th that it will be the first domestic company to participate in the first official project of CancerX, a public-private partnership to promote the Biden administration's cancer conquest policy, "Cancer Moonshot."

The public-private partnership CancerX for the U.S. cancer conquest project Cancer Moonshot announced its first official project, introducing Lunit as the first case of a cancer diagnosis solution company. The Lunit introduction page within the 'Solution Catalog' project officially announced by CancerX.
[Photo by Lunit]

On the 8th (local time), CancerX announced "The Solutions Catalog," a digital solutions guide for cancer diagnosis and treatment for medical institutions across the United States, introducing Lunit as the first case for cancer diagnosis among the 14 participating companies. The Solutions Catalog is the first concrete project announced since CancerX recruited members to conquer cancer, representing a digital innovation strategy to improve access to cancer treatment and reduce patients' financial burdens.

CancerX divided The Solutions Catalog into three areas: cancer diagnosis, treatment and care, and treatment management, providing a guide to actively utilize commercialized digital products and solutions in each field at U.S. medical institutions. Accordingly, medical institutions across the United States can now immediately use digital cancer diagnosis and treatment products and solutions from the 14 companies introduced in The Solutions Catalog.

Lunit will focus on providing the Lunit INSIGHT product line in the cancer diagnosis area of The Solutions Catalog and plans to actively contribute to the U.S. government's cancer conquest project through early diagnosis of lung and breast cancer. Since joining CancerX as the first domestic founding member in June, Lunit has been participating in various activities.

Seobum Seok, CEO of Lunit, said, "In the U.S., statistics show that 4 out of 10 cancer patients spend all their lifelong savings during cancer treatment, indicating a significant financial burden on patients. CancerX’s initiative to enable U.S. medical institutions to use Lunit’s AI solutions for early cancer diagnosis is expected to reduce patients’ medical expenses while greatly contributing to easing national healthcare finances."

In addition to Lunit, The Solutions Catalog includes global companies providing cancer diagnosis and treatment-related solutions, such as Flatiron Assist, an independent subsidiary of Roche specializing in cancer patient care, and Grail, a blood test cancer diagnosis company acquired by global genome analysis equipment company Illumina.

This content was produced with the assistance of AI translation services.